The application of TAK1 inhibitors in osteoarthritis might be especially attractive regarding the possibility of pain-relief in patients since TAK1 has been shown to be part of the increased nerve growth factor production in osteoarthritic synovium [108]. This evidence concerns the gene MAP3K7 and osteoarthritis.